Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 for PD-L1–positive recurrent or metastatic cervical cancer
CTR20201814Phase 2Terminated
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in cervical cancer (mCC), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Sep 2020; status: terminated.
02
Drugs
benmelstobart
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on CTR20201814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201814.